Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effects of HIM2

Diabetes Technology and Therapeutics

Volumn 4, Issue 4, 2002, Pages 459-466

  Clement, Stephen ^a   Still, J Gordon ^a   Kosutic, Gordana ^a   McAllister, R G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEXYL INSULIN MONOCONJUGATE 2; INSULIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; PORTAL VEIN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VERTIGO;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; POLYMERS;

EID: 0036379293     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091502760306544     Document Type: Article

References (17)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Eaton RP, Allen RC, Schade DS, Standefer JC: "Normal" insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care 1980;3:270-273.
3. Schade DS, Eaton RP: Insulin delivery: how, when, and where. N Engl J Med 1985;312:1120-1121.
4. Aoki TT, Benbarka MM, Okimura MC, Arcangeli MA, Walter RM Jr, Wilson LD, Truong MP, Barber AR, Kumagai LF: Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus. Lancet 1993;342: 515-518.
5. Hoffman A, Ziv E: Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 1997;33:285-301.
6. Shojaee-Moradie F, Powrie JK, Sundermann E, Spring MW, Schuttler A, Sonksen PH, Brandenburg D, Jones RH: Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 2000;23:1124-1129.
7. Turner RC: The U.K. Prospective Diabetes Study: a review. Diabetes Care 1998;21(Suppl 3):C35-C38.
8. Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991;4:1283-1288.
9. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitis: a randomized prospective 6 year study. Diabetes Res Clin Pract 1995;28:103-117.
10. Beylot M, Sautot G, Dechaud H, Cohen R, Riou J, Serusclat P, Mornex R: Lack of beta-adrenergic role for catecholamines in the development of hyperglycemia and ketonaemia following acute insulin withdrawal in type I diabetic patients. Diabetes Metab 1985;11: 111-117.
11. Husband DJ, Pernet A, Gill GV, Hanning I, Alberti KG: The metabolic response to insulin deprivation in idiopathic brittle diabetes. Diabetes Res 1986;3:193-198.
12. Vaughn N, Rao R, Kurtz A, Buckell H, Spathis G: Strict nocturnal diabetic control diminishes subsequent glycemic escape during acute insulin withdrawal. Metabolism 1986;35:136-142.
13. Milles J, Baylis P, Wright A: Plasma vasopressin during insulin withdrawal in insulin-dependent diabetes. Diabetologia 1981;20:607-611.
14. Larsen S, Hilsted J, Philipsen E, Tronier B, Damkjaer Nielsen M, Worning H: The effect of insulin withdrawal on intermediary metabolism in patients with diabetes secondary to chronic pancreatitis. Acta Endocrinol 1991;124:510-515.
15. Diem P, Robertson R: Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal. Br J Clin Pharmacol 1991;32:563-567.
16. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P, Bolli GB: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994;37:713-720.
17. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC: Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 2000;85:4491-4499.